Oryzon Genomics - Encouraging safety data in PORTICO
Oryzon Genomics has announced promising preliminary blinded aggregate safety data from its ongoing Phase IIb PORTICO trial at the 10th European Conference on Mental Health. The study is investigating the use of vafidemstat, the company’s lead asset in central nervous system (CNS) indications, for the treatment of borderline personality disorder (BPD). From the initial randomised 43 enrolled patients, no serious adverse events were reported, indicating that treatment was well tolerated. Additionally, following review by the independent data monitoring committee for PORTICO, the study received approval to continue. We see this as positive for the clinical development of vafidemstat, ensuring the trial remains on track to deliver interim readouts in Q123, representing the next major catalyst for the PORTICO trial. We continue to value Oryzon at €802m, or €15.1/share.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.